January 8, 2025
Odyssey Therapeutics Appoints Jason Haas as Chief Financial Officer
October 28, 2024
Odyssey Therapeutics and Terray Therapeutics Enter Strategic Collaboration to Jointly Discover and Develop First-in-Class Transcription Factor Therapies
October 27, 2024
Odyssey Therapeutics to Present New Data on its Clinical-Stage RIPK2 Scaffolding Inhibitor, OD-07656, at the American College of Gastroenterology (ACG) Annual Scientific Meeting 2024
October 2, 2024
Odyssey Therapeutics Appoints Biopharma Veterans Timothy P. Walbert and Ian F. Smith to its Board of Directors
September 27, 2024
Odyssey Therapeutics Announces Formation of Scientific Advisory Board
